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Abstract
Purpose: The induction of tissue-localized virus-speciﬁc CD8
T-cell response is essential for the development of an effective
therapeutic vaccine against genital diseases, such as cervical
cancer and genital herpes. Here, we aimed to elucidate the
immunologic role of IL7 in the induction of mucosal cellular
immunity.
Experimental Design: IL7 was engineered through Fc fusion to
enhancemucosal delivery across the genital epithelial barrier. The
immunomodulatory role of IL7 was evaluated by monitoring the
kinetics of various immune cells and measuring the expression of
chemokines and cytokines after intravaginal administration of Fc-
fused IL7 (IL7-Fc). The antitumor effects of intramuscular human
papillomavirus (HPV) DNA vaccine or topical IL7-Fc alone or
in a combinational regimen on mice survival were compared
using a orthotopic cervical cancer model.
Results: Intravaginal treatment of IL7-Fc, but not native IL7,
induces upregulation of chemokines (CXCL10, CCL3, CCL4, and
CCL5), cytokines (IFNg , TNFa, IL6, and IL1b), and an adhesion
molecule (VCAM-1) in the genital tract, leading to the recruitment
of several leukocytes, including CD4, CD8, gd T cells, and den-
dritic cells. Importantly, in this murine cervical cancer model,
topical administration of IL7-Fc after intramuscular HPV DNA
vaccination increases the number of HPV-speciﬁc CD8 T cells in
the genital mucosa, but not in the spleen, leading to stronger
antitumor activity than the HPV DNA vaccine alone.
Conclusions: Our ﬁndings provide an important insight into
the immunomodulatory role of IL7-Fc via topical application
and the design of therapeutic vaccine regimen that induces
effective genital–mucosal CD8 T-cell responses. Clin Cancer Res;
22(23); 5898–908. 2016 AACR.
Introduction
Cervical cancer is one of the most common causes of cancer-
related deaths in women worldwide. Almost all cases are caused
by infection with high-risk types of human papillomavirus (HPV;
ref. 1). Among them, HPV16 and -18 account for about 70% to
75% of patients with cervical cancer (2). Clonal expansion of
persistently infected cells leads to a premalignant cervical intrae-
pithelial neoplasia (CIN), which then gradually transforms into
invasive cancer (3). Although the prophylactic HPV vaccines can
efﬁciently prevent HPV infection, they do not have therapeutic
effects against preexisting infection and HPV-induced lesions (4).
The most common treatment for CIN3 is surgical excision, which
is associated with pregnancy-related complications and a 10%
recurrence rate (5). More seriously, the mortality rate of cervical
cancer after conventional treatment is more than 50% (6). Thus,
there is an urgent need for an effective nonsurgical therapeutic
approach to eradicate HPV-associated CIN and cervical cancer.
HPV-speciﬁc CD8 T-cell responses have been suggested to play
a dominant role in the resolution of HPV infection (7, 8), and
therapeutic vaccines are now being designed to induce a robust,
yet speciﬁc, T-cell response. To date, several different types of
therapeutic vaccines have been evaluated in patients with high-
grade CIN (CIN2/3; ref. 3). However, considering the spontane-
ous regression rate ofCIN2/3 (11%–30%), vaccineswith a clinical
response rate of 11% to 49.5% have shown limited success in
improving the overall response rate (9–11). Although most of
these vaccines increase the vaccine-induced blood CD8 T-cell
response, systemic CD8 T-cell response did not speciﬁcally cor-
relate with clinical outcome. The limited efﬁcacy of therapeutic
vaccines was related to inadequate T-cell trafﬁcking to mucosal
dysplastic area (12). Thus, current studies have highlighted the
crucial role of local cellular immunity for therapeutic intervention
(13–15). Recently, we have shown that electroporation-delivered
immunization with a novel HPV DNA vaccine elicited strong
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HPV-speciﬁc CD8 T-cell responses in most patients with CIN3.
Speciﬁcally, the clinical study showed that seven of the nine
patients (78%) displayed complete regression of their neoplastic
lesion. However, this clinical study did not elucidate the induc-
tion of tissue-localized HPV-speciﬁc CD8 T-cell response and its
correlation with clinical outcomes (7). Thus, targeting vaccine-
induced T-cell responses to the genital lesion should be important
in the development of an effective therapeutic vaccine against the
HPV-related genital disease.
Several groups have been developing treatment regimen to
recruit HPV-speciﬁc T cells into the genital lesion. Local admin-
istration of toll-like receptor (TLR) 7 and 9 agonists, imiquimod
or CpG, after parenteral HPV16 E7 vaccination has been shown to
induce accumulation of E7-speciﬁc CD8 T cells in the genital tract
and regression of genital tumors (16, 17). However, in humans,
imiquimod use can induce severe adverse events, including, but
not limited to, acute and severe local inﬂammation andulceration
(18, 19), while treatment of CpG requires repeated injections due
to short-lived efﬁcacy (17). In addition, some studies have dem-
onstrated the ability of cytokines, such as IL2 and IL15, to serve as
mucosal vaccine adjuvants in animal models to enhance the
therapeutic efﬁcacy (20, 21). However, these cytokines induced
antibody-secreting plasma cells rather than CD8 T-cell responses
in the mucosal tissues. Therefore, there is still a clinical need to
develop a safe and highly effective therapeutic regimen for induc-
ing local CD8 T-cell response against genital lesion.
IL7 is known to be an essential factor in the proliferation and
homeostasis of T cells. Exogenous IL7 treatment with various
types of vaccines enhanced the cytolytic activity of CD8 T cells
(22) and the generation of long-lasting memory T cells (23),
indicating that IL7might be an ideal vaccine adjuvant to improve
CD8 T-cell response to vaccine antigens. However, these studies
typically focused on the function of IL7 in the lymphatic system,
while its role in the induction of CD8 T-cell response at the genital
tract has not been reported previously.
The neonatal Fc receptor (FcRn) is present in mucosal epithelia
(lung, intestine, and genital mucosa) and is involved in the
transport of IgG antibodies across the epithelial barrier (24).
Studies have shown that the FcRn/IgG axis could be used to
enhance the transport of mucosally introduced Fc-fused proteins
(25, 26). Thus, the approach of delivering the desired cytokine
through an Fc fusionmay provide a valuable tool for investigating
the immunomodulatory role of cytokine in mucosal tissue.
In this study and for the ﬁrst time, we have elucidated the
immunomodulatory role of Fc-fused IL7 (IL7-Fc) in the genital
tract. After intravaginal administration, IL7-Fc more efﬁciently
crossed the genital epithelial barrier in an FcRn-dependent man-
ner thannative IL7.We also demonstrated that intravaginal IL7-Fc
administration signiﬁcantly augmented recruitment of CD4,
CD8, and gd T cells, as well as dendritic cells (DC) in the genital
tract, presumably due to induction of various chemokines, cyto-
kines, and an adhesion molecule. More importantly, topical IL7-
Fc administration following intramuscular HPV DNA immuni-
zation enhanced the accumulation of vaccine-inducedCD8T cells
in the cervicovaginal (CV) tissue, which correlated well with
genital tumor suppression. Taken together, these results suggest
that the topical IL7-Fc application with systemic vaccination is a
potentially effective therapeutic strategy for not only enhancing
tissue-localized CD8 T-cell response but also eradicating virus-
induced premalignant and malignant mucosal lesions.
Materials and Methods
Animal
Female C57BL/6 mice, 8 to 10 weeks of age, were purchased
from The Jackson Laboratory. All animals were housed under
speciﬁc pathogen-free conditions in the animal care facility in
Pohang University of Science and Technology (Pohang, Gyeong-
buk, Republic of Korea). The procedures of animal experiments
were performed in accordance with the NIH (Bethesda, MD)
guidelines for mouse experiments. The protocol was approved
by the Institutional Animal Care and Use Committee (IACUC).
Preparation and treatment
The codon-optimized human IL7 (27) and G-CSF gene were
individually fused with a hybrid Fc-fragment, which contains the
upper CH2domain of IgD, and the last CH2 andCH3domains of
IgG4 (28). The schematic structure of Fc-fused IL7 is presented in
Supplementary Fig. S1. Chinese hamster ovary (CHO) cells were
stably transfected with a plasmid encoding IL7-Fc or G-CSF-Fc,
and proteins were prepared as described previously (29). Recom-
binant human IL7 (rIL7), puriﬁed from HEK 293E cells, was
purchased from BioLegend. Detailed descriptions of cytokine
treatment, FTY720 treatment, HPV DNA vaccine (GX188) immu-
nization, and electroporation are provided in Supplementary
Materials and Methods.
Distribution and retention of ﬂuorescence-conjugated IL7-Fc
in the genital tract
IL7-Fc was coupled with Cy-5.5 monoreactive NHS ester
according to the manufacturer's instructions (GE Healthcare).
Eluted proteins were desalted and concentrated by using centrif-
ugal ﬁlter devices (MerckMillipore), and protein concentration of
the dye-labeled IL7-Fc was measured using an anti-human IL7
ELISA set (SouthernBiotech). Diestrus mice were intravaginally
administered with an equivalent signal intensity of Cy-5.5–coju-
ganted IL7-Fc (1 mg/kg) or unconjugated Cy-5.5 in PBS. Further
details are provided in Supplementary Materials and Methods.
Translational Relevance
Systemic HPV-speciﬁc CD8 T-cell response does not specif-
ically correlate with disease clearance. However, clinical trial
data for assessing the therapeutic efﬁcacy of HPV vaccine
suggest that high levels of intralesional CD8 T cells are asso-
ciated with beneﬁcial outcomes. Thus, the induction of vac-
cine-induced T-cell responses in the mucosal lesion is crucial
for developing an effective therapeutic vaccine. In this study,
intramuscular HPV DNA immunization in combination with
topical IL7-Fc administration increases the recruitment of
vaccine-induced CD8 T cells into genital tract, providing
synergistic antitumor activity against established cervicovagi-
nal tumor inmice. This study suggests that topical treatment of
IL7-Fc is well tolerated and safe and that the combination
regimen of IL7-Fc and HPV DNA vaccine (GX188E) is syner-
gistic, potentially supporting further studies in humans. This
study demonstrates a novel strategy for the use of IL7-Fc as a
safe mucosal immunomodulator for inducing local cellular
immunity against mucosal tumor and infectious disease.
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Quantiﬁcation of cytokines and chemokines in the CV cells
To measure the levels of the chemokines and cytokines in CV
cell culture supernatant, 1  106 CV cells were maintained in
RPMI1640, supplemented with 10% FBS (HyClone), 100 U/mL
penicillin, and 100 mg/mL streptomycin (Invitrogen) for 2 days
prior to supernatant collection. The levels of chemokines and
cytokines were estimated with a MILLIPLEX MAP Mouse Cyto-
kine/Chemokine Kit (Millipore).
Immunohistochemical staining and quantiﬁcation of
ﬂuorescence intensity
Tissues were embedded in optimal cutting temperature com-
pound (Tissue-Tek), frozen in liquid nitrogen. Frozen blocks were
cut into 7-mmthick sections,ﬁxed in acetone, followed by staining
with anti-CD31 (MEC13.3, BioLegend) and VCAM-1 (429
(MVCAM.A), BioLegend). For the quantiﬁcation of ﬂuorescence
intensity, a previously described method was employed (30).
Further details are provided in Supplementary Materials and
Methods.
Splenocytes and CV cell preparation
Spleen and CV tissue were surgically excised using sterile
technique. The splenocytes were obtained by gentle mechanical
disruption. For the preparation of CV cells, the uterine horns were
removed from the genital tract, and CV tissue was minced and
digested with 1 mg/mL collagenase D (Roche) and 0.5 mg/mL
DNase (Sigma-Aldrich). The cells were passed through a 40-mm
strainer (BD), washed, and resuspended with RPMI1640 contain-
ing 10% FBS and antibiotics.
Flow cytometry analysis
Cells were stained with the appropriate combination of the
monoclonal antibodies (mAbs). Detailed information of anti-
bodies and tetramer staining method is provided in Supplemen-
tary Materials and Methods.
In vivo tumor experiments
The TC-1/luc cell line, TC-1 cotransformed with the HPV16 E6,
E7 gene and transfected with a luciferase gene, was kindly pro-
vided by Professor T.-C.Wu (Johns HopkinsMedical Institutions,
Baltimore, MD; ref. 31). Each diestrus mouse was intravaginally
inoculated with 1  105 TC-1/luc cells by using the methods
described previously (32). Further details are provided in Sup-
plementary Materials and Methods.
Statistical analysis
A two-tailed paired Student t test was used to evaluate the
statistical difference between the two experimental groups. For in
vivo tumor experiments, differences in survival rates between
groups were determined by a log-rank test using the Prism 5.0
software (GraphPad).
Results
FcRn-mediated transcytosis of Fc-fused IL7 in genital tract
As FcRn enhances Fc-mediated transcytosis across genital epi-
thelial cells, we ﬁrst examined whether IL7-Fc could be efﬁciently
delivered into genital tract tissues. After mice were treated with
topical Cy-5.5–conjugated IL7-Fc (Cy5.5–IL7-Fc) or unconjugated
Cy-5.5 (Cy5.5), we determined the distribution and the amount of
the ﬂuorochrome by using quantitative ﬂuorescence imaging. The
intensity of Cy5.5–IL7-Fc signiﬁcantly increased 1 day after treat-
ment and was observed until day 7 in the CV tissue. In particular,
the signal intensity in CV tissue of Cy5.5–IL7-Fc treated mice was
6- or 4.5-fold higher than that of Cy5.5 alone treated mice at 1 or 7
days after treatment, respectively. Moreover, the ﬂuorescent signal
was detected atmeasurable levels in various anogenital tissues (i.e.,
cervix-vagina, uterus, ovary, and rectum) of Cy5.5–IL7-Fc treated
mice, but not in the Cy5.5-treated mice (Fig. 1A). Thus, the Fc
fusion approach can enhance mucosal epithelial barrier penetra-
tion at the local level and the retention of IL7 in genital tract after
topical treatment. Interestingly, a higher level of ﬂuorescence was
observed not only in the genital tract tissues but also in the liver,
kidney, and spleen in mice treated with Cy5.5–IL7-Fc than those
treated with Cy5.5 at 1 and 7 days after treatment, indicating that
transcytosed IL7-Fc can circulate throughout the body (Fig. 1A).
To conﬁrm whether intravaginal (IVAG) administration of IL7-Fc
penetrates mucosal epithelial lining and allows systemic circula-
tion, we measured the serum concentration of IL7 after mice were
intravaginally treated with either rIL7 or IL7-Fc. Mice treated with
IL7-Fc, but not rIL7, exhibited signiﬁcantly increased level of IL7
compared with PBS control (Supplementary Fig. S2). These data
are in close agreement with the previous study that demonstrated
an increased level of IgG in the serum of wild-type mice but not
of FcRn-KO mice after IVAG injection, indicating that FcRn in
mucosa epithelium can mediate transcytosis of Fc-fused protein
in the genital tract (26). Taken together, Fc fusion to IL7 markedly
improves the genital epithelial barrier transcytosis after local
administration.
Substantial increase of T-cell inﬁltration in genital tract after
local application of IL7-Fc
As IL7 is known to have multiple functional roles in regulating a
variety of immune cells (23, 33, 34), we analyzed the change of
leukocyte populations in the CV tissue after topical IL7-Fc treat-
ment. Local delivery increased the absolute numbers of CD4 and
CD8 T cells (Table 1; Fig. 1B). This increase of genital tract T cells
peaked at day 7 after IL7-Fc treatment and gradually decreased to
the baseline levels by day 14 (Table 1). Moreover, the number of
CD4 or CD8 T cells was signiﬁcantly increased by about 20-fold or
10-fold, respectively, 7 days after IL7-Fc administration compared
with the baseline levels (Table 1). Of note, the absolute numbers
of CD44highCD62Llow effector CD4 and CD8 T cells were signif-
icantly increased at day 7 and waned in a similar pattern to the
total CD4 and CD8 T cells over time (Table 1; Fig. 1B), whereas the
number of T cells did not change after topical rIL7 treatment
(Fig. 1B). These results of T-cell kinetic proﬁle and immunomod-
ulatory effect agree with our recent study on the T-cell immuno-
modulatory effect of topical applied IL7-Fc in the lungs (35).
Interestingly, the majority of the CD4 T cells were found in the
submucosa, whereas CD8 T cells preferentially localized in the
epithelium after IVAG treatment of IL7-Fc (Supplementary Fig.
S3). Overall, topical IL7-Fc delivery causes the inﬁltration of CD4
and CD8 T cells, which display distinct migration patterns in the
genital tract.
Intravaginal administration of IL7-Fc also increased the
absolute numbers of gd T cell and monocyte-derived DC
(CD11bþCD11cþMHCIIþ) at day 3. Although slightly numerical-
ly superior, in the CV tissue of IL7-Fc–treated mice, the conven-
tional genital DCs (CD11bCD11cþMHCIIþ) were not signiﬁ-
cantly different from the baseline levels at day 3. The number of gd
T cells, conventional DCs, andmonocyte-derived DCs also peaked
at day 7, at which they increased up to about 45-, 6-, and 8-fold,
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Figure 1.
FcRn-mediated transcytosis of IL7-Fc and recruitment of T cells in CV tissue by intravaginal administration of IL7-Fc, but not IL7 and G-CSF-Fc. A, C57BL/6
wild-type mice (n ¼ 3/group) were intravaginally administered with Cy-5.5 or Cy-5.5–conjugated IL7-Fc. Fluorescent images (left) and bar graph depicting
ﬂuorescence intensity (right) of the various organs at day 1 and 7 are shown.B,Mice (n¼ 6/group) were treated with PBS, IL7, IL7-Fc, or G-CSF-Fc. After 7 days, CD4
and CD8 T cells in the CV tissue were analyzed by ﬂow cytometry. Left, data are representative dot plots of T cells in CV tissue; middle, absolute number
of CD4 or CD8 T cell counts; right, absolute numbers of CD62LloCD44high subsets in CD4 or CD8 T-cell populations.C,Mice (n¼ 4/group)were treated intravaginally
with PBS or IL7-Fc. One day later, FTY720 was administered twice at 3-day intervals. CD4 and CD8 T cells in CV tissue were analyzed by ﬂow cytometry
at day 7. Representative dot pots (left) and frequency (right) of T cells in CV tissue. Data, shown as means  SEMs, are representative of two independent
experiments.  , P < 0.05;  , P < 0.01 by Student t test.
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respectively, compared with the baseline levels. Interestingly, a
higher cell count was still observed until day 21 for gd T cells and
day 14 for conventional and monocyte-derived DC. Thus, these
data indicate that IVAG application of IL7-Fc induces local accu-
mulation of T cells and DCs (Table 1).
As the inﬁltration of various immune cells may contribute to
bystander tissue damage (18, 19), we assessed the toxicity of ﬁve
repeated weekly treatments of IL7-Fc administered in different
dosages (0, 0.8, 3, and 8 mg/kg/dose) in rats (Supplementary
Table S1). There were no adverse events in terms of anatomic
pathology of CV tissues (Supplementary Table S1A) and vaginal
irritation scores (Supplementary Table S1B), indicating that top-
ical IL7-Fc administration was well tolerated and safe in the
genital tract.
To clarify whether the immunomodulatory activity of IL7-Fc
is speciﬁc to the activity of IL7, we compared the frequency of
CD4 and CD8 T cells after topical administration of irrelevant
Fc-fused cytokine, G-CSF (G-CSF-Fc). As shown in Fig. 1B, the
absolute numbers of genital T cells in mice treated with G-CSF-
Fc were not signiﬁcantly different from that of PBS-treated
mice. In addition, Fc-fragment alone also did not induce T-
cell accumulation in the genital tract (Supplementary Fig. S4).
Importantly, treatment of anti-IL7Ra antibody abrogated the
inﬁltration of T cells, suggesting that T cell–modulatory activity
of IL7-Fc in CV tissue might be mediated by IL7R (Supplemen-
tary Fig. S5). Taken together, IL7, but not the Fc-fragment, has
the critical role in the accumulation of T cells at CV by topical
IL7-Fc treatment.
Next, we investigated whether the increased T cells were
recruited from systemic circulation or proliferated in the local
area. Mice that were given IL7-Fc were treated with FTY720, which
is known to block T-cell migration from lymph nodes. As shown
in Fig. 1C, FTY720 treatment signiﬁcantly abrogated the number
of CD4 and CD8 T cells, indicating that IVAG IL7-Fc treatment
recruits CD4 and CD8 T cells from systemic circulation into CV
tissues.
To verify whether the delivery route of IL7-Fc was important
for T-cell recruitment in CV tissues, mice were treated with IL7-
Fc either through intravaginal or subcutaneous routes. A higher
level of serum IL7 was observed in mice treated subcutaneously
compared with those treated intravaginally (Supplementary
Fig. S6A), whereas the extent of CD4 or CD8 T-cell accumula-
tion was greater by IVAG administration than subcutaneous
injection (Supplementary Fig. S6B and S6C). Thus, these data
suggest that changes in the immune environment of the genital
tract induced by local IL7-Fc administration are critical for T-
cell recruitment.
Increase of chemokines, cytokines, and an adhesion molecule
expression in the genital tract by topical IL7-Fc treatment
Chemokines and cytokines have crucial roles in the recruitment
of immune cells into the genital tract tissue. Chemoattractants,
such as CXCL10, CCL3, CCL4, and CCL5, as well as cytokines
(IFNg , TNFa, IL6, and IL1b) arewell-known soluble factors for the
recruitment of leukocytes into the genital tract (36). Thus, we
evaluated the effect of IL7-Fc treatment on the expression of these
chemokines and cytokines in the CV cells. Remarkably, chemo-
kines, such as ligands for CXCR3 (CXCL10), CCR1 and CCR3
(CCL5), and CCR5 (CCL3, CCL4, CCL5), and cytokines (IFNg ,
TNFa, IL6, and IL1b) were signiﬁcantly increased after IL7-Fc
treatment. Overall, chemokines and cytokines were upregulated
at day 1 and peaked at day 3, to then decline rapidly to baseline
levels by day 7 after IL7-Fc administration (Fig. 2A andB). As these
chemokines and cytokines are known to induce the inﬂux of
various immune cells, such as T cells, immature DCs, monocytes,
into the inﬂamed tissue (36, 37), the enhanced inﬁltration of T
cells by IL7-Fc treatment (Table 1; Fig. 1B) might be mediated by
the induction of these soluble factors. In addition to the chemo-
kines and cytokines, the selective expression of cell adhesion
molecules on the local vascular endothelium is crucial for the
migration of T cells into the peripheral tissues. Therefore, we
examined the expression of the representative adhesionmolecule,
VCAM-1, in the CV after IVAG treatment of IL7-Fc. As shown
in Fig. 2C, IL7-Fc treatment, but not PBS, substantially induced
VCAM-1 expression on the local vascular endothelium. Collec-
tively, these results suggest that migration of leukocytes from
blood to genital tract may be facilitated by the expression of
adhesion molecules as well as the expression of different chemo-
kines and cytokines in the genital tract after IL7-Fc administration.
Increased local accumulation of HPV DNA vaccine-induced
CD8 T cells by intravaginal administration of IL7-Fc
To investigate whether IVAG treatment of IL7-Fc can be an
effective therapeutic vaccine regimen for inducing antigen-spe-
ciﬁc CD8 T cells at the genital tract tissue, mice were vaccinated
with GX188E, a novel HPV therapeutic vaccine (7), twice at a
7-day interval, and IL7-Fc was intravaginally administered at
the last vaccination point. One week after treatment, HPV E7-
speciﬁc CD8 T cells in spleen or CV cells were enumerated by
tetramer staining with TetE7 (H-2Db–restricted E749-57 peptide-
loaded tetramer) or TetL1 (irrelevant HPV16 L1165-173 peptide-
loaded tetramer as a negative control). A similar number of
HPV16 E7-speciﬁc CD8 T cells were induced in the spleen
regardless of IL7-Fc administration. As CXCR3 expression on
CD8 T cells is an important factor of T-cell recruitment into
Table 1. Kinetics of CV leukocytes after intravaginal IL7-Fc treatment
Absolute cell number after IL7-Fc treatment
Day 0 Day 3 Day 7 Day 14 Day 21
Total CD4 T cells (103) 2.86  0.49 12.76  0.53a 51.51  9.18a 3.33  0.77 2.57  0.44
CD62Llo CD44high CD4 T cells (103) 2.21  0.31 10.26  0.68a 35.06  7.03a 2.51  0.72 2.13  0.41
Total CD8 T cells (103) 0.49  0.08 1.65  0.18a 6.21  0.76a 0.65  0.17 0.84  0.30
CD62Llo CD44high CD8 T cells (103) 0.11  0.01 0.64  0.11a 1.96  0.29a 0.23  0.10 0.27  0.14
gd T cells (103) 0.61  0.14 2.40  0.30a 28.58  3.88a 2.05  0.56a 1.80  0.07a
Conventional DC (103) 0.33  0.07 0.48  0.09 2.15  0.31a 1.02  0.12a 0.56  0.04
Monocyte-derived DC (103) 4.78  0.28 10.15  0.83a 38.89  2.10a 14.66  2.16a 5.64  1.03
NOTE: Mice (n¼ 3/group) were intravaginally administered with IL7-Fc at 0, 3, 7, 14, and 21 days prior to sacriﬁce. Absolute numbers of leukocytes in the CV tissue
were calculated on the basis of the percentage of total cell number with ﬂow cytometry. Data, shown as means  SEMs, are representative of two independent
experiments.
aP < 0.05 by Student t test compared with cell numbers on day 0.
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inﬂamed tissue (38), we also analyzed the level of CXCR3-
expressing HPV16 E7-speciﬁc CD8 T cells harvested from the
spleen. The absolute number of CXCR3þHPV16 E7-speciﬁc
CD8 T cells in the spleen seemed to be lower in mice treated
with GX188E plus IL7-Fc compared with GX188E alone
(Fig. 3A). On the other hand, a combination of GX188E with
IL7-Fc signiﬁcantly increased the number of HPV16 E7-speciﬁc
CD8 T cells to a greater extent than GX188E alone in the CV
tissue. Mice treated with GX188E and IL7-Fc also displayed a
signiﬁcantly higher number of CXCR3þHPV16 E7-speciﬁc CD8
T cells in CV tissue compared with those treated with DNA
vaccine alone (Fig. 3B). The relatively lower number of
CXCR3þHPV16 E7-speciﬁc CD8 T cells in spleen may be due
to the migration of vaccine-induced T cells into the CV tissue by
the locally expressed chemoattractants. Taken together, these
data show that IVAG treatment of IL7-Fc with parenteral HPV
DNA vaccination enhances the accumulation of vaccine anti-
gen-speciﬁc CD8 T cells in the CV.
Enhanced antitumor effects induced by HPV DNA vaccination
in the orthotopic murine cervical cancer model by topical
treatment of IL7-Fc
We next investigated whether topical treatment of IL7-Fc could
further enhance the antitumor efﬁcacy of HPV DNA vaccination.
To this end, mice were intravaginally challenged with luciferase-
expressing TC-1 tumor cells (TC-1/luc) and treated with GX188E
and IL7-Fc 7 days after tumor inoculation (Fig. 4A). When we
measured tumor burden by examining bioluminescence signal
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Induction of various chemokines and cytokines in the CV cells and VCAM-1 on local vascular endothelium after topical treatment of IL7-Fc. Mice (n¼ 4/group) were
intravaginally administered with IL7-Fc and sacriﬁced to harvest CV tissue at indicated days after application. The level of chemokines and cytokines in
the CV cell culture supernatant was analyzed by ELISA. The concentrations of chemokines (CXCL10, CCL3, CCL4, and CCL5; A) and cytokines (IFNg , TNFa, IL6,
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intensities and survival rate, untreated mice showed rapid tumor
growth and succumbed rapidly after tumor challenge. In contrast,
IL7-Fc alone showed delayed tumor growth rate compared with
untreated mice, and signiﬁcant antitumor effect was shown in
mice treated with GX188E alone. Most notably, mice cotreated
with GX188E vaccine and IL7-Fc exhibited markedly delayed
tumor growth and enhanced survival rate even compared
with those treated with GX188E alone (Fig. 4B and C). To
further determine the role of CD8 T cells in combinatory antitu-
mor therapeutic efﬁcacy, vaccine plus IL7-Fc adjuvant-treated
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Figure 3.
Increase of HPV DNA vaccine-induced E7-speciﬁc CD8 T cells in CV tissue, but not in spleen, by topical administration of IL7-Fc. Mice (n ¼ 4/group) were
vaccinated with GX188E DNA via intramuscular injection. After 7 days, mice were boosted with GX188E DNA in combination with or without intravaginal IL7-Fc
application. One week after the second immunization, spleen and cervicovaginal tissue were harvested and analyzed by ﬂow cytometry. A, Representative
dot plots (left) and absolute number of TetE749-57
þCD8 T cells (top right) and absolute number of CXCR3þTetE749-57
þCD8 T cells (bottom right) in the spleen. n.s.,
not signiﬁcant. B, Representative dot plots (left) and absolute number of TetE749-57
þCD8 T cells (top right) and absolute number of CXCR3þTetE749-57
þCD8
T cells (bottom right) in the CV tissue. Data, shown as means  SEMs, are representative of three independent experiments.  , P < 0.05 by Student t test.
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mice were injected with either isotype or CD8 T cell–depleting
antibodies after tumor challenge. As shown in Fig. 4D, mucosal
tumor control was abolished in CD8 T cell–depleted mice, indi-
cating that CD8 T cells have a crucial role in the augmented
antitumor activity by HPV DNA vaccine with IL7-Fc.
Discussion
Here, we have demonstrated that Fc-fused IL7 can be efﬁciently
delivered across the genital epithelial barrier in an FcRn-depen-
dent manner after topical delivery. Importantly, after intramus-
cular HPV DNA vaccination to generate a systemic CD8 T-cell
response, a single intravaginal application of IL7-Fc can provide
superior antitumor activity against orthotopic cervical cancer,
likely by increasing the recruitment of vaccine-induced CD8 T
cells into the genital tract. These results provide a novel insight
into the role of IL7 as a vaccine adjuvant and highlight several
clinical implications. First, this study deﬁnes, for the ﬁrst time, the
immunomodulatory role of IL7 in the genital tract by Fc fusion
approach to enhance mucosal delivery. This study also showed
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that local IL7-Fc administration markedly increased the recruit-
ment of various leukocytes through the upregulation of adhesion
molecule, as well as numerous chemokines, and cytokines at the
mucosal site. Second, topical IL7-Fc treatment can elicit better
migration of HPV DNA vaccine-induced CD8 T cells into genital
tract compared with vaccine alone, which correlated with tumor
control. Thus, this combined regimen potentially improves the
efﬁcacy of therapeutic DNA vaccine by inducing mucosal cellular
immunity and can also be an important ﬁrst step in providing a
pathway to design effective therapy for curing patients with HPV-
related genital lesions. Finally, as FcRn has been also detected in
the other mucosal tissue, such as lung and intestine, our ﬁndings
give a rational strategy for inducing immune response, particu-
larly T-cell response, in othermucosal tissues and protection from
a variety of infectious mucosal diseases and cancers.
This study also showed that Fc-fused IL7 more efﬁciently
crossed the genital epithelial layer than rIL7 via topical admin-
istration (Supplementary Fig. S2). In our previous study, the
serum IL7 level was comparable in mice treated with either IL7-
Fc or rIL7 immediately after intraperitoneal injection, and the
in vivo IL7-Fc level declined more slowly than rIL7 due to the
prolonged circulating half-life by Fc fusion (27). In contrast, in
this study, the serum IL7 level was initially undetectable (Sup-
plementary Fig. S2), suggesting that Fc fusion to IL7 is more
important for crossing the genital epithelium rather than half-
life extension in mucosal delivery. In addition, topical admin-
istration of IL7-Fc induced T-cell accumulation in the genital
tract (Fig. 1B), wherein genital CD4 and CD8 T cells were each
localized in the submucosa and epithelium, respectively (Sup-
plementary Fig. S3). This result is supported by a previous
observation that the localization patterns of CD4 and CD8
T cells are distinct in the genital tract (39). Notably, tissue-
localized CD4 T cells were clustered in the vaginal submucosa
and required for the migration of CD8 T cells into the epithe-
lium through the secretion of cytokine and induction of the
local chemokine gradient (40, 41). Moreover, we demonstrated
that local treatment of IL7-Fc elicited expression of various
soluble mediators in the tissue, such as chemokines, cytokines,
as well as a cell adhesion molecule (VCAM-1) on vascular
endothelium in the genital tract (Fig. 2). These results are in
agreement with previous reports that circulating CD8 T cells are
rapidly recruited to the genital tract after local expression of
inﬂammatory chemokines (30, 42). We also showed that
treatment of FTY720 abrogated the accumulation of T cells in
the CV tissue (Fig. 1C). Taken together, it is likely that immu-
nomodulatory activities of topical IL7-Fc treatment induce
recruitment of T cells from systemic circulation rather than
the proliferation of locally resident T-cell population, pre-
sumably due to the expression of tissue localization signals
in the genital mucosa that seem to be critical for T-cell
recruitment.
Topical administration of IL7-Fc treatment attracted activated
T cells and also innate immune cells, including conventional DCs
andmonocyte-derivedDCs. Notably, a signiﬁcant increase of gd T
cells in genital tract tissues was also observed (Table 1). Given that
the immunomodulatory effects of IL7 were induced by an IL7Ra
(CD127)–dependent manner (Supplementary Fig. S5), IL7R-
expressing cells such as ab (CD4, CD8) and gd T cells that
participate in the mucosal immunity might be involved in the
recruitment of various leukocytes. Although ab and gd T cells
augment the cytotoxic response and express a similar set of
cytokines upon activation, gd T cells play critical roles in imme-
diate host defense because gd T cells expandmore rapidly than ab
T cells (43, 44). Consistently, in topical IL7-Fc–treated mice, the
extent of expansion in gd T cell (46.8-fold) was more remarkable
than that of CD4 or CD8 T cell (18.1-fold or 12.7-fold,
respectively) 7 days after treatment compared with baseline levels
(Table 1). Because of gd T-cell capacities, a topical application of
IL7-Fc could confer partial protection to genital tumor (Fig. 4C).
Moreover, gd T cells secrete cytokines and chemokines, including
IFNg , CCL3, CCL4, and CCL5 (45, 46). Secretion of IFNg in the
reproductive tract induces the expression of VCAM-1 on local
vascular endothelium, which leads to the recruitment of system-
ically circulating T cells (42). In addition, the expression of
CXCL10, which is largely IFNg dependent, is chemotactic for
CXCR3þ T cells and important for antitumor activity (47). In
this regard, local treatment of IL7-Fc could presumably induce the
expression of CXCL10 in CV tissue (Fig. 2A) and attract CXCR3þ
CD8 T cells into the genital tract (Fig. 3B). Furthermore, consid-
ering that CCL3 and CCL4, and CCL5 have been known to act as
chemoattractants forDCs (48), theymaymediate DC recruitment
into the genital tract after local IL7-Fc application. Thus, gd T cells
as an initial responder may orchestrate mucosal immunity after
intravaginal IL7-Fc treatment by secreting chemokines and cyto-
kines at the genital mucosa, and inducing adhesion molecules in
the local vasculature, leading to the recruitment of several leuko-
cytes into the genital tract.
In our previous study, we found that Fc-fused IL7 could alter
pulmonary immune environment after intranasal treatment
(35). In addition, this study showed that FcRn in the lung was
indispensable for transcytosis and immunomodulation of IL7-
Fc, which is consistent with this study's results of immuno-
modulatory activity in the genital tract. Similar kinetics of
immune cell recruitment, including CD4, CD8, and gd T cells,
has also shown in the respiratory tract after local administra-
tion. This phenomenon might be mediated by similar IL7-
responsive cells residing in both the lung and genital tract.
Interestingly, the lung-retentive polyclonal CD4 T cells, which
were induced by IL7-Fc alone, had prophylactic effects against
inﬂuenza infection (35), whereas tumor-speciﬁc CD8 T cells
induced by IL7-Fc and HPV DNA vaccine played an essential
role for therapeutic effects in the mucosal tumor suppression.
Overall, topical IL7-Fc administration into FcRn-expressing
mucosal tissues induces T-cell modulation, suggesting that the
topical IL7-Fc application can be used as a mucosal adjuvant to
confer protective and therapeutic immunity against virus infec-
tion at mucosal tissues.
Imiquimod, one of the known agents against genital diseases,
increases the number of CD8 T cells in neoplastic lesion of the
vulvar area through TLR7-mediated enhancement of innate
immune responses, including secretion of cytokines (19). In
addition, imiquimod facilitates HPV DNA vaccine-induced
CD8 T-cell accumulation in the genital tract, leading to tumor
control in a mouse cervical cancer model (16). However, in
patients, severe local inﬂammations and ulcerations caused by
excessive production of proinﬂammatory cytokines with repeat-
ed topical treatments limit the therapeutic potential and wider
adoption (18, 19). Although proinﬂammatory responses were
transiently induced by the topical IL7-Fc delivery, repeated
injections did not cause observable adverse effects in anatomic
pathology or vaginal irritation (Supplementary Table S1).
Another safety concern in the human application of IL7-Fc
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can be immunogenicity, from an immune response against Fc
component (49). When we measured for antidrug antibody
(ADA) in sera of the IL7-Fc–treated cynomolgus monkeys, ADA
was detected in subcutaneously treated monkeys without affect-
ing patterns of pharmacokinetics and pharmacodynamics
between ADA-positive and -negative monkeys, suggesting that
ADA dose not neutralize the activity of IL7-Fc in monkeys
(data not shown). We assume that the main factor for ADA
induction in monkeys may account for the amino acid differ-
ence of IL7 and Fc-fragment between humans and monkeys. In
fact, other Fc-fused proteins (EPO-Fc, G-CSF-Fc, and hGH-Fc),
which are fused with same Fc-fragment, also generated ADA
in monkeys. Importantly, these proteins do not induce immu-
nogenicity-related adverse events and ADA production in a total
of 531 human volunteers in phase I/IIa clinical trials (EPO-Fc:
NCT02291991/NCT02044653, G-CSF-Fc: NCT01951027/
EudraCT 2015-002693-20, and hGH-Fc: EudraCT 2013-
002771-18/EudraCT 2014-002698-13 and EudraCT 2015-
001939-21). Furthermore, the commercialized Fc-fused pro-
teins, including abatacept (CTLA4-IgG1) and etanercept
(TNFR-IgG1), induce ADA in humans, but these antibodies do
not affect the drug efﬁcacy (50). Taken together, although it will
be necessary to address the immunogenicity issues of IL7-Fc in
future study, we speculate that the application of IL7-Fc in
humans may be safe and does not cause immunogenicity-
related problems.
Surgical treatment of HPV-related intraepithelial lesion does
not permanently eradicate HPV and is associated with high
recurrence rates (51). Thus, development of effective immu-
notherapy is important to prevent recurrence. IL7 as a vaccine
adjuvant plays critical roles in the transition of effector cells to
memory CD8 T cells and enhances the generation of vaccine-
induced long-term memory CD8 T cells (23). This study sug-
gests that vaccine-speciﬁc memory CD8 T cells induced by IL7
might be more potent than those induced by vaccine alone in
preventing reinfection. Thus, even though it is not clear whether
IL7-Fc can enhance the generation of memory CD8 T cells in the
genital tract, it gives rise to the possibility that these T cells may
prevent recurrent genital diseases, such as CINs and genital
herpes.
In conclusion, our ﬁndings provide a novel role of IL7 in
promoting cellular immunity in the genital mucosa. In addition,
topical IL7-Fc administration along with HPV DNA vaccine is a
safe and potent strategy for enhancing therapeutic efﬁcacy
against HPV-related genital disease. Furthermore, this study can
promote a series of future investigations on the use of IL7-Fc as a
mucosal modulator for treating other mucosal cancers and
infectious diseases.
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